Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

About this update from Gain Therapeutics, Inc.

BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ. Details of the oral presentation are as follows:Presentation Title: “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease”Presenter:Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of GainSession Name:In the pipeline: updates from pharma on ongoing preclinical studies and clinical trialsDate:May 22, 2026Time:4:15-4:30pm MST Management will also attend the 7th World Parkinson’s Congress, being held May 24-27, 2026, in Phoenix, AZ. About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting. Compelling data in these models, demonstrating a disease-modifying effect of GT-02287, suggest that the drug candidate may have the potential to slow or stop the progression of Parkinson’s disease. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with an increase in GCase activity among those receiving GT-02287 at clinically relevant doses. GT-02287 is currently being evaluated in a Phase 1b clinical trial for the ...

View stock analysis, news, and events for Gain Therapeutics, Inc.